 Chiasma, Inc. CHMA, a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that the U.S. Food and Drug Administration FDA accepted for review the New Drug Application NDA resubmission for its oral octreotide capsules investigational product candidate, conditionally trade named MYCAPSSA. Chiasma is developing MYCAPSSA for the maintenance treatment of adults with acromegaly. 